Welcome to our dedicated page for Pluri news (Ticker: PLUR), a resource for investors and traders seeking the latest updates and insights on Pluri stock.
About Pluri Inc. (Nasdaq: PLUR)
Pluri Inc. is a biotechnology company pioneering innovative, cell-based solutions to address global challenges in medicine, food production, and agriculture. Leveraging its proprietary three-dimensional (3D) cell expansion platform, Pluri transforms cells into scalable, high-quality products designed to promote global wellbeing and sustainability. The company’s cutting-edge technology enables mass production of cell-based products with unmatched consistency, scalability, and cost efficiency, positioning it as a leader in the biotechnology and cellular agriculture sectors.
Core Technology and Capabilities
At the heart of Pluri’s operations is its patented 3D cell expansion platform. This state-of-the-art system mimics natural cellular environments, allowing for the efficient cultivation of various cell types at industrial scales. The platform is fully automated, highly controlled, and validated for Good Manufacturing Practice (GMP) compliance, ensuring batch-to-batch consistency and regulatory readiness. Pluri’s technology has been successfully applied across multiple domains, including regenerative medicine, foodtech, and agricultural technology (agtech).
Business Segments
- Regenerative Medicine: Pluri develops cell-based therapies for conditions such as inflammation, ischemia, and hematological disorders. Its placental expanded (PLX) cells, derived from human placenta, are designed to stimulate the body’s natural healing processes without the need for tissue or genetic matching. These therapies address critical medical needs, including acute radiation syndrome (H-ARS) and neurodegenerative diseases.
- Foodtech: Through its subsidiary, Ever After Foods, Pluri applies its cell-expansion technology to cultivated meat production. This platform enables the creation of slaughter-free, sustainable meat products with superior taste, texture, and nutritional value. By reducing production costs and increasing scalability, Pluri is driving the commercialization of ethical, cultivated food solutions.
- Agricultural Technology (Agtech): Pluri collaborates with industry leaders to develop cell-based agricultural products aimed at improving food security and sustainability. These initiatives focus on reducing environmental impact and creating scalable alternatives to traditional farming methods.
- Contract Development and Manufacturing Organization (CDMO): Pluri offers its advanced manufacturing expertise to life science companies, providing end-to-end solutions from preclinical development to commercial-scale production. This includes partnerships to produce cell therapies for conditions like ALS and diabetes.
Market Position and Competitive Edge
Pluri operates in highly competitive markets, including cell therapy, cultivated food, and sustainable agriculture. Its key differentiator is its proprietary 3D cell expansion technology, which enables scalable, cost-effective production of cell-based products. The company’s ability to serve diverse industries while maintaining regulatory compliance and production efficiency positions it as a versatile and reliable partner. Strategic collaborations further enhance its market presence, as seen in partnerships with global leaders in foodtech, biotechnology, and agriculture.
Strategic Collaborations
Pluri has established partnerships with renowned organizations to accelerate innovation and commercialization. Notable collaborations include its work with Wilk Technologies to develop cell-based medical foods, its joint venture with Tnuva in cultivated meat, and its CDMO agreements with companies like Kadimastem and BrainStorm Cell Therapeutics. These alliances leverage Pluri’s technological expertise to address unmet needs across industries.
Commitment to Sustainability
Pluri’s mission extends beyond technological innovation to include a strong commitment to sustainability. By providing scalable alternatives to traditional methods in medicine, food production, and agriculture, the company aims to reduce environmental impact, promote ethical practices, and improve global food security.
Conclusion
Pluri Inc. stands at the forefront of the biotechnology revolution, offering transformative solutions that span regenerative medicine, foodtech, and agtech. Its proprietary 3D cell expansion platform is a cornerstone of its success, enabling the scalable production of high-quality, cell-based products. Through strategic collaborations and a commitment to sustainability, Pluri is well-positioned to address critical global challenges and drive innovation across multiple industries.
Pluri Inc. (PLUR) has signed an exclusive collaboration agreement with Hemafund to enhance Ukraine's radiation emergency preparedness. The three-year partnership focuses on stockpiling and distributing Pluri's PLX-R18 cell therapy as a countermeasure against Hematopoietic Acute Radiation Syndrome (H-ARS).
The collaboration aims to build an initial capacity of 12,000 doses of PLX-R18, sufficient to treat 6,000 individuals. If successful, the initiative could generate over $100 million in value for both parties. Hemafund will leverage its biobank infrastructure for storage and distribution across Ukraine.
This strategic initiative comes in response to recent security concerns, including a Russian drone strike on the Chernobyl nuclear power plant. The partnership encompasses:
- Secure storage and distribution systems
- Regulatory compliance support
- Clinical advancement opportunities
- Public and private funding initiatives
Ever After Foods (EAF) and Bühler announced a strategic collaboration to develop commercial-scale cultivated meat production systems. The partnership aims to bring to market a production system that enables commercial production at ten-fold lower scale than existing technologies.
The collaboration leverages EAF's proprietary edible packed-bed (EPB™) technology platform, which can reduce production costs by over 90% while achieving superior production efficiency. The system enables natural production of both muscle and fat tissues for beef, chicken, duck, and fish cells, ensuring exceptional replication of conventional meat.
EAF's technology offers enhanced nutritional value and superior flavor, working with select cultivated meat companies and industry leaders to accelerate global deployment. The partnership with Bühler aims to develop tailored solutions for sustainable scaling of cultivated meat production, moving beyond pharma-based technologies toward food-specific production methods.
Pluri Inc. (PLUR) has secured an additional $3.5 million investment from Merchant Adventure Fund, L.P., a major existing shareholder, bringing total recent financings to $10 million. The investment follows a recent $6.5 million private placement with global investor Alejandro Weinstein.
The new investment involves issuing 759,219 common shares at $4.61 per share and warrants to purchase 45,553 shares at $5.568 per share. The closing is expected around February 20, 2025. The recent $6.5 million investment from Weinstein includes an agreement to acquire Kokomodo and potentially enter the cacao market.
The funds will support Pluri's growth strategy as a global leader in cell-based technology, enabling expansion across pharma, foodtech, and agtech industries. The company views this additional investment as a strong vote of confidence in its vision, technology, and execution strategy.
Pluri Inc. (PLUR) has secured a $6.5 million strategic investment from global investor Alejandro Weinstein at $4.61 per share, representing a premium to market. The investment includes common shares, warrants, and pre-funded warrants. Concurrently, Pluri is acquiring a 71% stake in Kokomodo , an AgTech company specializing in cultivated cacao production, for $4.5 million in Pluri common shares.
The transactions aim to strengthen Pluri's position in sustainable food technologies. As part of the deal, Weinstein will join Pluri's Board of Directors. The investment closing is expected around January 31, 2025, while the Kokomodo acquisition is anticipated to complete in Q2 2025. Both transactions require shareholder approval and other regulatory clearances.
The global cacao market, valued at $13.5 billion in 2023, is projected to reach $23.5 billion by 2030 with an 8.2% CAGR.
Pluri Inc. (PLUR) congratulates Mesoblast on receiving FDA approval for the first MSC-based therapy treating steroid-refractory acute graft-versus-host disease (SR-aGVHD). This milestone validates the therapeutic potential of Mesenchymal Stromal Cell (MSC) therapies in regenerative medicine. Pluri's CEO Yaky Yanay emphasized how this approval marks a significant advancement in cellular medicine and demonstrates the potential of regenerative therapies to transform healthcare by addressing root causes rather than just symptoms.
Pluri continues developing its proprietary 3D cell-expansion technology for MSC therapies, including PLacental eXpanded cells for treating conditions like Acute Radiation Syndrome and Knee Osteoarthritis.
Pluri Inc. (Nasdaq: PLUR) has been shortlisted for the CDMO of the Year Award by the Advanced Therapies Awards 2025 for its PluriCDMO™ business division. Launched in January 2024, PluriCDMO™ offers contract development and manufacturing services to life science companies, providing access to their 47,000 square foot GMP facilities and patented bioreactor system for 3D cell expansion.
The nomination comes less than a year after the division's launch, highlighting Pluri's rapid progress in supporting transformative therapies. The company's technology enables mass-scale production through a fully controlled, automated, and validated process, serving a growing number of innovative clients in the cell therapy industry.
Pluri Inc. (Nasdaq: PLUR) is evaluating its readiness for mass production of PLX-R18, a potential treatment for hematopoietic complications of acute radiation syndrome (H-ARS). The assessment comes amid heightened global nuclear threats, particularly in Ukraine. PLX-R18 has shown promise in improving survival and accelerating recovery from H-ARS in preclinical studies, with support from U.S. defense agencies. The treatment has received FDA's Orphan Drug Designation and IND approval for H-ARS treatment. The company's manufacturing facility is equipped for large-scale cellular therapy production and could be mobilized for mass production if needed.
Pluri Inc. (NASDAQ: PLUR), a biotechnology company specializing in cell-based solutions, has announced its participation in the upcoming Q4 Virtual Investor Summit Microcap Event on November 21st. The company will deliver a presentation from 9:00 AM to 9:30 AM ET and will be available for one-on-one meetings throughout the day.
The event showcases 40 micro-cap companies with catalysts and strong market performance. It features live Q&A sessions and is complimentary for qualified investors. The presentation will be accessible via webcast.
BrainStorm Cell Therapeutics has signed a Memorandum of Understanding (MOU) with Pluri to manufacture NurOwn® for the planned Phase 3b trial in amyotrophic lateral sclerosis (ALS). This agreement will enable BrainStorm to transfer its manufacturing technology and start production at Pluri's GMP-compliant facility in Israel upon finalizing a definitive agreement. The collaboration aims to meet the supply requirements for the Phase 3b trial and explore future commercial distribution options, pending NurOwn's approval. The trial will enroll up to 200 participants and is designed in two parts: a 24-week double-blind period followed by a 24-week open-label period. The primary endpoint is the change in ALSFRS-R score from baseline to week 24. BrainStorm will provide further updates in Q4 2024.
Pluri Inc. (PLUR) announces a collaboration with Bar-Ilan University's BIRAD, funded by the Israel Innovation Authority, to advance cancer immunotherapy using Placental Mucosal Associated Invariant T (MAIT) cells for solid tumors. The partnership combines Pluri's proprietary MAIT cell expansion platform with Prof. Cyrille Cohen's Siglec-based Chimeric Switch Receptors technology to enhance CAR-MAIT's efficacy and tumor specificity. The project aims to develop innovative allogeneic cell therapies targeting solid tumors, addressing a significant unmet medical need. Pluri's MAIT cells, derived from human placentas, offer unique advantages including potency, multiple tumor-targeting mechanisms, and reduced risk of Graft versus Host Disease.
FAQ
What is the current stock price of Pluri (PLUR)?
What is the market cap of Pluri (PLUR)?
What is Pluri Inc.'s core technology?
What industries does Pluri Inc. operate in?
How does Pluri differentiate itself from competitors?
What are Pluri’s key business segments?
What are some examples of Pluri’s strategic collaborations?
What is the significance of Pluri’s PLX cells?
How does Pluri contribute to sustainability?
What is Pluri’s role in the cultivated meat industry?
What is PluriCDMO?
What are the applications of Pluri’s 3D cell expansion platform?
